Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer

NCT02625441 is registered in ClinicalTrials.gov with Helsinki University Central Hospital as lead sponsor.

NCT NCT02625441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02625441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer
Lead sponsor
Helsinki University Central Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 31, 2015
Completion date
June 1, 2025
Enrollment
516 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer